<!DOCTYPE html>
<html>
<head>
    <title>BREAKING: Federal Register: Proposal To Refuse To Approve a New Drug Application Supplement for HETLIOZ (Tasimelteon); Opportunity for a Hearing</title>
    <meta charset="UTF-8">
    <style>
        body { font-family: Georgia, serif; max-width: 800px; margin: 0 auto; padding: 20px; }
        h1 { border-bottom: 2px solid #333; }
        .breaking { background: #fff3cd; border-left: 4px solid #dc3545; padding: 15px; }
        .source { background: #f8f9fa; padding: 10px; margin-top: 20px; font-size: 0.9em; }
        .timestamp { color: #666; }
    </style>
</head>
<body>
    <h1>BREAKING: Federal Register: Proposal To Refuse To Approve a New Drug Application Supplement for HETLIOZ (Tasimelteon); Opportunity for a Hearing</h1>
    <p class="timestamp">Published: 2022-10-11 | Source: Federal Register</p>
    <div class="breaking">
        <p><strong>The Director of the Center for Drug Evaluation and Research (Center Director) at the Food and Drug Administration (FDA or Agency) is proposing to refuse to approve a supplemental new drug application (sNDA) submitted by Vanda Pharmaceuticals, Inc. (Vanda), for HETLIOZ (tasimelteon) capsules, 20 milligrams (mg), in its present form. This notice summarizes the grounds for the Center Director's proposal and offers Vanda an opportunity to request a hearing on the matter.</strong></p>
    </div>
    <h2>Document Details</h2>
    <p><strong>Document Type:</strong> Notice</p>
    <p><strong>Agency:</strong> Health and Human Services Department, Food and Drug Administration</p>
    <p><strong>Document Number:</strong> 2022-21932</p>
    <p><strong>Publication Date:</strong> 2022-10-11</p>
    <h2>Official Source</h2>
    <p>Read the full document at: <a href="https://www.federalregister.gov/documents/2022/10/11/2022-21932/proposal-to-refuse-to-approve-a-new-drug-application-supplement-for-hetlioz-tasimelteon-opportunity">https://www.federalregister.gov/documents/2022/10/11/2022-21932/proposal-to-refuse-to-approve-a-new-drug-application-supplement-for-hetlioz-tasimelteon-opportunity</a></p>
    <div class="source"><strong>Source:</strong> Federal Register - 2022-21932</div>
    <p><a href="index.html">Back to Breaking News Wire</a></p>
</body>
</html>
